- Previous Close
23.44 - Open
23.27 - Bid 16.77 x 100
- Ask 23.14 x 100
- Day's Range
22.62 - 23.48 - 52 Week Range
14.90 - 38.12 - Volume
227,034 - Avg. Volume
1,162,425 - Market Cap (intraday)
2.196B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-1.45 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.12
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
edgewisetx.comRecent News: EWTX
View MorePerformance Overview: EWTX
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EWTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EWTX
View MoreValuation Measures
Market Cap
2.23B
Enterprise Value
1.77B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.01%
Return on Equity (ttm)
-34.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-133.81M
Diluted EPS (ttm)
-1.45
Balance Sheet and Cash Flow
Total Cash (mrq)
470.17M
Total Debt/Equity (mrq)
1.03%
Levered Free Cash Flow (ttm)
-63.22M